Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

First Urology PSC

Neither a doctor nor a teaching hospital

Research payments

$7,221,197

1,477 payments

Through program year 2025, First Urology PSC is reported as receiving $7,221,197 in research payments, across 1,477 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,852,084 209
2024 Research $2,476,460 248
2023 Research $584,413 243
2022 Research $331,234 203
2021 Research $475,428 187
2020 Research $818,716 209
2019 Research $682,861 178

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $4,565,125 331 payments
  2. Pfizer Inc. $932,247 288 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $489,107 307 payments
  4. Dendreon Pharmaceuticals LLC $459,076 55 payments
  5. Medivation Inc. $387,242 371 payments
  6. Ferring Pharmaceuticals AS $112,525 24 payments
  7. Astellas Pharma Global Development $67,203 15 payments
  8. AbbVie, Inc. $65,391 32 payments
  9. Ferring International Pharmascience Center US $42,113 11 payments
  10. Boston Scientific Corporation $22,066 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc $2,085,745 61 payments
  2. A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) $1,035,509 70 payments
  3. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $880,816 635 payments
  4. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $328,671 8 payments
  5. A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo $308,823 29 payments
  6. Open-label external control arm study of darolutamide plus A $233,636 133 payments
  7. A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) $208,299 3 payments
  8. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Provent $178,501 8 payments
  9. A Multi Center Open Label Single arm Phase 2 Study of Abiraterone Acetate Plus Prednisone in subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease $127,254 11 payments
  10. A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca $123,274 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record